Narcan developer to be acquired by Indivior
Bio Pharma Dive
NOVEMBER 14, 2022
The deal, which could carry a total value of roughly $145 million, is in large part focused on a nasal formulation of the opioid overdose drug nalmefene
Development Related Topics 
282 
Rankings: Research and Development
Pharmaceutical Technology
NOVEMBER 1, 2022
What is Research and Development (R&D)? This category includes organisations that have demonstrated a commitment to the research and development of new products and/or new processes. This category highlights companies that have advanced drug development research.
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Black Diamond spins out new biotech to develop cancer drugs
Bio Pharma Dive
DECEMBER 13, 2022
Months after restructuring and trimming its workforce, the company has teamed up with its original investors to form an antibody drug developer called Launchpad Therapeutics
FDA rejects two China-developed cancer drugs
Bio Pharma Dive
MAY 2, 2022
The regulator cited concerns around single-country trials in turning back Hutchmed's pancreatic cancer treatment, while manufacturing issues held up Junshi and Coherus' throat cancer medicine
Mandatory COVID Vaccination Policy Template
Advertiser: Aggregage
The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.
UTSA researchers to develop compounds for GBM tumours
Pharmaceutical Technology
JANUARY 25, 2023
A researchers’ team from the University of Texas at San Antonio’s (UTSA) Department of Chemistry and its partners are developing compounds to treat Glioblastoma multiforme (GBM) tumours. The post UTSA researchers to develop compounds for GBM tumours appeared first on Pharmaceutical Technology.
Lilly and ProQR to expand genetic medicine development agreement
Pharmaceutical Technology
DECEMBER 23, 2022
Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.
Roche takes over development of Biogen-partnered lymphoma drug
Bio Pharma Dive
DECEMBER 19, 2022
Glofitimab, part of a long-standing collaboration between the two companies that’s resulted in Rituxan and Ocrevus, will be the responsibility of Roche, which will pay out royalties
Visual system brain development implicated in infants who develop autism
Scienmag
MAY 25, 2022
Social & Behavioral Science autism brain develop development implicated infants system visual
Vertex invests in a rare disease drug and its developer
Bio Pharma Dive
DECEMBER 8, 2022
The big biotech is paying Entrada Therapeutics $250 million up front to grab rights to an experimental treatment for myotonic dystrophy type 1 in the latest bid to build its pipeline
Cyagen and Neurophth partner to develop gene therapy vectors
Pharmaceutical Technology
NOVEMBER 8, 2022
Cyagen and Neurophth Therapeutics have entered a strategic partnership to jointly develop next-generation AAV gene therapy vectors for specific kinds of genetic ophthalmic ailments.
Capsida Biotherapeutics and Prevail to develop CNS gene therapies
Pharmaceutical Technology
JANUARY 5, 2023
Capsida Biotherapeutics and Eli Lilly and Company ’s wholly owned subsidiary Prevail Therapeutics have announced a partnership for the development of non-invasive gene therapies for central nervous system (CNS) diseases.
Cloud robotics labs are accelerating drug discovery and development
Pharmaceutical Technology
OCTOBER 28, 2022
Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development.
Astellas takes stake in gene therapy developer Taysha
Bio Pharma Dive
OCTOBER 24, 2022
Already an investor in gene therapy, the Japanese pharma will buy 15% of the Texas biotech’s stock and gain options to two gene therapies for central nervous system disorders
Eisai and Washington University to develop neurodegenerative disease therapies
Pharmaceutical Technology
DECEMBER 15, 2022
Eisai has entered a comprehensive research partnership agreement with Washington University School of Medicine in St Louis, US, to develop potential new therapies for neurodegenerative ailments.
Umoja and IASO partner to develop therapies for haematological malignancies
Pharmaceutical Technology
NOVEMBER 22, 2022
Umoja Biopharma has signed a research agreement with IASO Biotherapeutics (IASO Bio) to develop off-the-shelf therapies for haematological malignancies. The post Umoja and IASO partner to develop therapies for haematological malignancies appeared first on Pharmaceutical Technology.
Kite and Arcellx enter partnership for multiple myeloma therapy development
Pharmaceutical Technology
DECEMBER 12, 2022
Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients.
Prevail, Capsida partner to develop gene therapies for nervous system diseases
Bio Pharma Dive
JANUARY 4, 2023
The Lilly-owned subsidiary will pay $55 million to gain access to Capsida’s AAV gene therapy technology in a deal aimed at central nervous system disorders
Qurient partners with TB Alliance to develop telacebec
Pharmaceutical Technology
FEBRUARY 6, 2023
South Korean biotechnology company Qurient has entered a licence agreement with TB Alliance for the development and commercialisation of telacebec (Q203). It will be developed to treat tuberculosis (TB) and other non-tuberculosis mycobacteria (NTM) infections.
Merck and Moderna partner to develop and sell cancer vaccine
Pharmaceutical Technology
OCTOBER 14, 2022
German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs.
Tetra and Cellvera partner to develop oral Covid-19 treatment
Pharmaceutical Technology
SEPTEMBER 8, 2022
Tetra Bio-Pharma and Cellvera have entered an agreement to jointly develop ARDS-003 as an oral combination therapeutic candidate with 400mg Qifenda (Favipiravir) for Covid-19. Developed by FujiFilm Toyama Chemical, Favipiravir is currently owned by Cellvera.
Boost agility and speed in your drug development research
Bio Pharma Dive
OCTOBER 31, 2022
How flexible API access to integrated 'omics data helps boost agility and speed in drug research
Novartis confirms it has stopped development of experimental Huntington’s drug
Bio Pharma Dive
FEBRUARY 1, 2023
Termination of the branaplam program, according to Novartis, was due to an “overall assessment of the risk-benefit profile” observed in a mid-stage clinical trial that raised safety concerns last year
2022 in review: Drug development milestones for tropical diseases
Pharmaceutical Technology
DECEMBER 16, 2022
Previously disrupted by the Covid-19 pandemic, this past year has seen a return of increased efforts and progress in the development of new treatments for tropical diseases. We ourselves took up activities related to developing Covid-19 vaccines,” says Duffy.
AlzeCure begins Alzheimer's therapy development phase
Pharma Times
JANUARY 11, 2023
Candidate will go through the development programme, which includes safety and tolerability studies
Hookipa partners with Roche for cancer immunotherapy development
Pharmaceutical Technology
OCTOBER 21, 2022
Hookipa Pharma and Roche have signed a strategic partnership and licence agreement for developing HB-700 and another undisclosed arenaviral immunotherapy. Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers.
Astellas to support development of Taysha’s gene therapy programmes
Pharmaceutical Technology
OCTOBER 25, 2022
Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN).
Lilly agrees to acquire gene therapy developer Akouos for $610m
Pharmaceutical Technology
OCTOBER 19, 2022
Akouos focuses on developing adeno-associated viral gene therapies to treat inner ear conditions, including sensorineural hearing loss. The post Lilly agrees to acquire gene therapy developer Akouos for $610m appeared first on Pharmaceutical Technology.
Merck stops coronavirus vaccine development in surprise setback
Bio Pharma Dive
JANUARY 25, 2021
The drugmaker, one of the largest vaccine developers globally, won't move forward with either of two candidates it's been testing after disappointing data in early trials
Supporting multi-audience communication in all stages of drug development
Bio Pharma Dive
DECEMBER 20, 2021
Biopharmaceutical companies have ongoing and extensive needs for print and digital communications throughout the drug development life cycle that can benefit from a single-source vendor
JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies
Bio Pharma Dive
JANUARY 10, 2023
Moderna’s Stéphane Bancel and Pfizer’s Albert Bourla hinted Monday at greater dealmaking to come for their companies, while Gilead gave investors an update on an important cancer drug trial
Alzheimer’s disease biomarkers galvanise rocky drug development space
Pharmaceutical Technology
DECEMBER 7, 2022
Alongside the discourse on what the positive study results could mean for patients, researchers are prioritising the development of more biomarkers to identify potential responders and improve patient outcomes.
FDA and NIH partner for neurodegenerative disease treatment development
Pharmaceutical Technology
SEPTEMBER 16, 2022
The US Food and Drug Administration (FDA) and the US National Institutes of Health (NIH) have unveiled a public-private partnership (PPP) to understand and develop treatments for neurodegenerative diseases.
FDA sets out advice to developers of gene editing medicines
Bio Pharma Dive
MARCH 16, 2022
Draft recommendations from the agency were generally straightforward, analysts said, although the document emphasized the potential safety risks of gene editing
Bain Capital backs new biotech startup developing oral asthma drug
Bio Pharma Dive
JULY 12, 2022
Areteia Therapeutics will receive $350 million from Bain and others to advance a drug that was previously licensed to Biogen for testing as an ALS treatment
ElevateBio and Affini-T collaborate to develop T cell therapies
Pharmaceutical Technology
NOVEMBER 16, 2022
Under the deal, the LentiPeak lentiviral vector technology platform and cell therapy production expertise of ElevateBio BaseCamp will be used by Affini-T to develop its investigational oncogenic driver programmes in the clinic.
Lonza expands team, labs for cell and gene development
BioPharma Reporter
OCTOBER 27, 2022
Lonza is to increase the size of the cell and gene therapy (CGT) development space at its Houston facility; the expansion will include viral vector-based process development and analytical development laboratories. Bio Developments
MD Anderson partners with Federation Bio to develop microbiome therapy
Pharmaceutical Technology
FEBRUARY 2, 2023
The University of Texas MD Anderson Cancer Center has announced a strategic collaboration with Federation Bio for the development of a new microbiome treatment for immunotherapy-resistant cancer patients.
In the News: November 2021 Regulatory and Development Updates
Camargo
DECEMBER 10, 2021
Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. 505(b)(2) Development Blog In the News Pediatrics Regulatory Strategy & Submissions
Alzheimer’s disease biomarkers galvanize rocky drug development space
Pharmaceutical Technology
DECEMBER 7, 2022
Alongside the discourse on what the positive study results could mean for patients, researchers are prioritising the development of more biomarkers to identify potential responders and improve patient outcomes.
Vaccine Developers of the Year: BioNTech and Moderna
Bio Pharma Dive
DECEMBER 9, 2020
Defying expectations, BioNTech and Moderna each designed and developed highly effective coronavirus shots far faster than previously considered possible
In the News: August 2021 Regulatory and Development Updates
Camargo
SEPTEMBER 8, 2021
Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. In the News: August 2021 Regulatory and Development Updates.
ALS drug approved by FDA in closely watched decision, marking win for patients, developer
Bio Pharma Dive
SEPTEMBER 30, 2022
The drug, which will be sold as Relyvrio, showed modest benefits in function and survival in testing. It also became the latest test of the FDA's flexibility toward new therapies for neurological disorders
Let's personalize your content